TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Devendra Hiwase; Christopher Hahn; Elizabeth Ngoc Hoa Tran; Rakchha Chhetri; Anmol Baranwal; Aref Al-Kali; Kirsty Sharplin; Dariusz Ladon; Rachel Hollins; Patricia Greipp; Monika Kutyna; Hassan Alkhateeb; Talha Badar; Paul Wang; David M. Ross; Deepak Singhal; Naranie Shanmuganathan; Peter Bardy; Ashanka Beligaswatte; David Yeung; Mark R. Litzow; Abhishek Mangaonkar; Pratyush Giri; Cindy Lee; Angie Yong; Noemi Horvath; Nimit Singhal; Raghu Gowda; William Hogan; Naseema Gangat; Mrinal Patnaik; Kebede Begna; Ing S. Tiong; Andrew Wei; Sharad Kumar; Anna Brown; Hamish Scott; Daniel Thomas; Chung H. Kok; Ayalew Tefferi; Mithun Vinod Shah

doi:10.1182/blood.2022018236

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Devendra Hiwase
, Christopher Hahn
, Elizabeth Ngoc Hoa Tran
, Rakchha Chhetri
, Anmol Baranwal
, Aref Al-Kali
, Kirsty Sharplin
, Dariusz Ladon
, Rachel Hollins
, Patricia Greipp
, Monika Kutyna
, Hassan Alkhateeb
, Talha Badar
, Paul Wang
, David M. Ross
, Deepak Singhal
, Naranie Shanmuganathan
, Peter Bardy
, Ashanka Beligaswatte
, David Yeung

Mark R. Litzow, Abhishek Mangaonkar, Pratyush Giri, Cindy Lee, Angie Yong, Noemi Horvath, Nimit Singhal, Raghu Gowda, William Hogan, Naseema Gangat, Mrinal Patnaik, Kebede Begna, Ing S. Tiong, Andrew Wei, Sharad Kumar, Anna Brown, Hamish Scott, Daniel Thomas, Chung H. Kok, Ayalew Tefferi, Mithun Vinod Shah

Research output: Contribution to journal › Letter › peer-review

37 Citations (Scopus)

Abstract

TO THE EDITOR:
Recent World Health Organization (WHO)1 classifications (5th edition), International Consensus Classification (ICC),2 and the European LeukemiaNet (ELN) guidelines3 included new categories for TP53-mutated (TP53mut) myeloid neoplasms (MNs) to acknowledge their uniformly poor outcomes and stimulate clinical research. However, there are critical differences in the details between these classifications, especially regarding single-hit TP53mut status, and their significance relating to therapy-related myeloid neoplasm (t-MN), a rare but often fatal malignancy diagnosed following exposure to cytotoxic therapies, remains unclear. Here, we report an international cohort consisting of t-MN with full characterization of TP53mut allele status and provide compelling evidence of poor outcome of TP53mut t-MN irrespective of the allelic status of TP53...

Original language	English
Pages (from-to)	1087-1091
Number of pages	5
Journal	Blood
Volume	141
Issue number	9
Early online date	28 Dec 2022
DOIs	https://doi.org/10.1182/blood.2022018236
Publication status	Published - 2 Mar 2023
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Neoplasms
Myeloid Neoplasia
Leukemia

Access to Document

10.1182/blood.2022018236Licence: In Copyright

Cite this

Hiwase, D., Hahn, C., Tran, E. N. H., Chhetri, R., Baranwal, A., Al-Kali, A., Sharplin, K., Ladon, D., Hollins, R., Greipp, P., Kutyna, M., Alkhateeb, H., Badar, T., Wang, P., Ross, D. M., Singhal, D., Shanmuganathan, N., Bardy, P., Beligaswatte, A., ... Shah, M. V. (2023). TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. Blood, 141(9), 1087-1091. https://doi.org/10.1182/blood.2022018236

@article{99c049669c7e4a0b99da1da79f4ec08b,

title = "TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype",

abstract = "TO THE EDITOR: Recent World Health Organization (WHO)1 classifications (5th edition), International Consensus Classification (ICC),2 and the European LeukemiaNet (ELN) guidelines3 included new categories for TP53-mutated (TP53mut) myeloid neoplasms (MNs) to acknowledge their uniformly poor outcomes and stimulate clinical research. However, there are critical differences in the details between these classifications, especially regarding single-hit TP53mut status, and their significance relating to therapy-related myeloid neoplasm (t-MN), a rare but often fatal malignancy diagnosed following exposure to cytotoxic therapies, remains unclear. Here, we report an international cohort consisting of t-MN with full characterization of TP53mut allele status and provide compelling evidence of poor outcome of TP53mut t-MN irrespective of the allelic status of TP53...",

keywords = "Neoplasms, Myeloid Neoplasia, Leukemia",

author = "Devendra Hiwase and Christopher Hahn and Tran, \{Elizabeth Ngoc Hoa\} and Rakchha Chhetri and Anmol Baranwal and Aref Al-Kali and Kirsty Sharplin and Dariusz Ladon and Rachel Hollins and Patricia Greipp and Monika Kutyna and Hassan Alkhateeb and Talha Badar and Paul Wang and Ross, \{David M.\} and Deepak Singhal and Naranie Shanmuganathan and Peter Bardy and Ashanka Beligaswatte and David Yeung and Litzow, \{Mark R.\} and Abhishek Mangaonkar and Pratyush Giri and Cindy Lee and Angie Yong and Noemi Horvath and Nimit Singhal and Raghu Gowda and William Hogan and Naseema Gangat and Mrinal Patnaik and Kebede Begna and Tiong, \{Ing S.\} and Andrew Wei and Sharad Kumar and Anna Brown and Hamish Scott and Daniel Thomas and Kok, \{Chung H.\} and Ayalew Tefferi and Shah, \{Mithun Vinod\}",

year = "2023",

month = mar,

day = "2",

doi = "10.1182/blood.2022018236",

language = "English",

volume = "141",

pages = "1087--1091",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "9",

}

Hiwase, D, Hahn, C, Tran, ENH, Chhetri, R, Baranwal, A, Al-Kali, A, Sharplin, K, Ladon, D, Hollins, R, Greipp, P, Kutyna, M, Alkhateeb, H, Badar, T, Wang, P, Ross, DM, Singhal, D, Shanmuganathan, N, Bardy, P, Beligaswatte, A, Yeung, D, Litzow, MR, Mangaonkar, A, Giri, P, Lee, C, Yong, A, Horvath, N, Singhal, N, Gowda, R, Hogan, W, Gangat, N, Patnaik, M, Begna, K, Tiong, IS, Wei, A, Kumar, S, Brown, A, Scott, H, Thomas, D, Kok, CH, Tefferi, A & Shah, MV 2023, 'TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype', Blood, vol. 141, no. 9, pp. 1087-1091. https://doi.org/10.1182/blood.2022018236

TY - JOUR

T1 - TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

AU - Hiwase, Devendra

AU - Hahn, Christopher

AU - Tran, Elizabeth Ngoc Hoa

AU - Chhetri, Rakchha

AU - Baranwal, Anmol

AU - Al-Kali, Aref

AU - Sharplin, Kirsty

AU - Ladon, Dariusz

AU - Hollins, Rachel

AU - Greipp, Patricia

AU - Kutyna, Monika

AU - Alkhateeb, Hassan

AU - Badar, Talha

AU - Wang, Paul

AU - Ross, David M.

AU - Singhal, Deepak

AU - Shanmuganathan, Naranie

AU - Bardy, Peter

AU - Beligaswatte, Ashanka

AU - Yeung, David

AU - Litzow, Mark R.

AU - Mangaonkar, Abhishek

AU - Giri, Pratyush

AU - Lee, Cindy

AU - Yong, Angie

AU - Horvath, Noemi

AU - Singhal, Nimit

AU - Gowda, Raghu

AU - Hogan, William

AU - Gangat, Naseema

AU - Patnaik, Mrinal

AU - Begna, Kebede

AU - Tiong, Ing S.

AU - Wei, Andrew

AU - Kumar, Sharad

AU - Brown, Anna

AU - Scott, Hamish

AU - Thomas, Daniel

AU - Kok, Chung H.

AU - Tefferi, Ayalew

AU - Shah, Mithun Vinod

PY - 2023/3/2

Y1 - 2023/3/2

N2 - TO THE EDITOR: Recent World Health Organization (WHO)1 classifications (5th edition), International Consensus Classification (ICC),2 and the European LeukemiaNet (ELN) guidelines3 included new categories for TP53-mutated (TP53mut) myeloid neoplasms (MNs) to acknowledge their uniformly poor outcomes and stimulate clinical research. However, there are critical differences in the details between these classifications, especially regarding single-hit TP53mut status, and their significance relating to therapy-related myeloid neoplasm (t-MN), a rare but often fatal malignancy diagnosed following exposure to cytotoxic therapies, remains unclear. Here, we report an international cohort consisting of t-MN with full characterization of TP53mut allele status and provide compelling evidence of poor outcome of TP53mut t-MN irrespective of the allelic status of TP53...

AB - TO THE EDITOR: Recent World Health Organization (WHO)1 classifications (5th edition), International Consensus Classification (ICC),2 and the European LeukemiaNet (ELN) guidelines3 included new categories for TP53-mutated (TP53mut) myeloid neoplasms (MNs) to acknowledge their uniformly poor outcomes and stimulate clinical research. However, there are critical differences in the details between these classifications, especially regarding single-hit TP53mut status, and their significance relating to therapy-related myeloid neoplasm (t-MN), a rare but often fatal malignancy diagnosed following exposure to cytotoxic therapies, remains unclear. Here, we report an international cohort consisting of t-MN with full characterization of TP53mut allele status and provide compelling evidence of poor outcome of TP53mut t-MN irrespective of the allelic status of TP53...

KW - Neoplasms

KW - Myeloid Neoplasia

KW - Leukemia

UR - https://www.scopus.com/pages/publications/85147307685

U2 - 10.1182/blood.2022018236

DO - 10.1182/blood.2022018236

M3 - Letter

C2 - 36574363

AN - SCOPUS:85147307685

SN - 0006-4971

VL - 141

SP - 1087

EP - 1091

JO - Blood

JF - Blood

IS - 9

ER -

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this